Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR408701 in Advanced Solid Tumors
NCT02187848Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Jul 2014
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of tusamitamab ravtansine in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 2 more (9 arms), sponsored by Sanofi. Primary endpoints: Number of dose limiting adverse events (every 2 week cycle) at 4 weeks, Overall Response Rate up to 40 months and 1 more. Started Jul 2014; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)gastric adenocarcinomasmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02187848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187848.